Literature DB >> 22878278

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Jørgen Vestbo1, Suzanne S Hurd, Alvar G Agustí, Paul W Jones, Claus Vogelmeier, Antonio Anzueto, Peter J Barnes, Leonardo M Fabbri, Fernando J Martinez, Masaharu Nishimura, Robert A Stockley, Don D Sin, Roberto Rodriguez-Roisin.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy document for the diagnosis and management of COPD. This executive summary presents the main contents of the second 5-year revision of the GOLD document that has implemented some of the vast knowledge about COPD accumulated over the last years. Today, GOLD recommends that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation. The document highlights that the assessment of the patient with COPD should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities. The first three points can be used to evaluate level of symptoms and risk of future exacerbations, and this is done in a way that splits patients with COPD into four categories-A, B, C, and D. Nonpharmacologic and pharmacologic management of COPD match this assessment in an evidence-based attempt to relieve symptoms and reduce risk of exacerbations. Identification and treatment of comorbidities must have high priority, and a separate section in the document addresses management of comorbidities as well as COPD in the presence of comorbidities. The revised document also contains a new section on exacerbations of COPD. The GOLD initiative will continue to bring COPD to the attention of all relevant shareholders and will hopefully inspire future national and local guidelines on the management of COPD.

Entities:  

Mesh:

Year:  2012        PMID: 22878278     DOI: 10.1164/rccm.201204-0596PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  1822 in total

1.  How do patients conceptualize chronic obstructive pulmonary disease?

Authors:  R E Goldman; L Mennillo; P Stebbins; D R Parker
Journal:  Chron Respir Dis       Date:  2016-12-19       Impact factor: 2.444

Review 2.  Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Authors:  Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

3.  Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation.

Authors:  C van de Bool; C Mattijssen-Verdonschot; P P M J van Melick; M A Spruit; F M E Franssen; E F M Wouters; A M W J Schols; E P A Rutten
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

4.  Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients.

Authors:  Rui Chen; Lin Lin; Jing-Wei Tian; Bin Zeng; Lei Zhang; Xin Chen; Hai-Yan Yan
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

5.  Persistent light to moderate alcohol intake and lung function: A longitudinal study.

Authors:  Monica M Vasquez; Duane L Sherrill; Tricia D LeVan; Wayne J Morgan; Joseph H Sisson; Stefano Guerra
Journal:  Alcohol       Date:  2017-09-01       Impact factor: 2.405

6.  Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk.

Authors:  Christine M Lusk; Angela S Wenzlaff; Donovan Watza; Jessica C Sieren; Natasha Robinette; Garrett Walworth; Michael Petrich; Christine Neslund-Dudas; Michael J Flynn; Thomas Song; David Spizarny; Michael J Simoff; Ayman O Soubani; Shirish Gadgeel; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-14       Impact factor: 4.254

Review 7.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

8.  Iron concentration in exhaled breath condensate decreases in ever-smokers and COPD patients.

Authors:  Andrew J Ghio; Joleen M Soukup; John McGee; Michael C Madden; Charles R Esther
Journal:  J Breath Res       Date:  2018-08-21       Impact factor: 3.262

9.  Lung function, respiratory symptoms and venous thromboembolism risk: the Atherosclerosis Risk in Communities Study.

Authors:  Y Kubota; S J London; M Cushman; A M Chamberlain; W D Rosamond; S R Heckbert; N Zakai; A R Folsom
Journal:  J Thromb Haemost       Date:  2016-11-08       Impact factor: 5.824

10.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.